Slide 1: Inspiring the World to Move Well
// 1 For personal use only INSPIRING THE WORLD TO MOVE WELL
Slide 2: Disclaimer
// 2 DISCLAIMER This presentation does not constitute investment, legal, taxation or other advice and the For personal use only presentation does not take into account your investment objectives, financial situation or particular needs. You are responsible for forming your own opinions and conclusio
Slide 3: Agenda
// 3 AGENDA For personal use only INSPIRING THE WORLD TO MOVE WELL™ • About dorsaVi REVOLUTIONARY • Operational update WEARABLE SENSOR TECHNOLOGY • ViSafe overview • ViMove overview • ViPerform overview • Outlook
Slide 4: About dorsaVi
For personal use only About dorsaVi // 4
Slide 5: Timeline
© dorsaVi | Timeline ; > 1995 2000 + Andrew Ronchi Sensor prototype began contemplating developing a medical device dorsaVi technology established! using government grants, by Andrew and Dan Ronchi development begins Theory that underpins 2004 tent protection prototype Version 3 released 2006 dorsaV
Slide 6: Board and Senior Management
BOARD AND SENIOR MANAGEMENT // 6 For personal use only Chairman Non Executive Director Non Executive Director Non Executive Director Herb Elliott Greg Tweedly Michael Panaccio Ash Attia Director & CEO Andrew Ronchi CFO CIO CPO CMO Head of Sales and Head of Sales and Head of Sales and Damian Connella
Slide 7: Our Business: Solid Foundation for Growth
// 7 OUR BUSINESS: SOLID FOUNDATION FOR GROWTH For personal use only • Three key business divisions with diversified revenue streams • Organisational health and safety • Clinical • Elite sports • Market leader with first mover advantage • Patent protected technology • Significant barriers to entry a
Slide 8: The Hardware and Products
// 8 THE HARDWARE AND PRODUCTS For personal use only • OHS solution to determine, measure and mitigate high risk activities • Patent protected movement algorithms • Significant appetite for innovative manual handling solutions on medical-grade sensor technology • Executive and board-level focus on r
Slide 9: For personal use only
gf Allianz @i) ry ( bhpbilliton \WWorksWell ie MONASH Ax pustinteattn NYSPORTSMED i ST. JUDE MEDICAL Se esiat
Slide 10: Operational Update
// 10 For personal use only Operational Update
Slide 11: Financial Overview
// 11 FINANCIAL OVERVIEW dorsaVi Customer Revenue For personal use only 2013 2014 2015 2016 Q1 2017 3,000 Revenue 398,607 529,380 1,358,218 3,019,000 1,004,000* EBITDA (2,148,749) (3,852,593) (8,684,709) (5,915,567) N/A 2,500 1,008 Loss from (1,659,235) (3,562,024) (8,036,161) (5,237,102) N/A contin
Slide 12: Strong Global Growth
// 12 STRONG GLOBAL GROWTH dorsaVi Sales Revenue For personal use only $2.0M $1.8M $1.6M $1.4M $1.2M Q4 $1.0M Q3 Q2 $0.8M Q1 $0.6M $0.4M $0.2M $0.0M FY2015 FY2016 FY2017 FY2015 FY2016 FY2017 FY2015 FY2016 FY2017 AU UK US
Slide 13: Execution Across the Product Lines
// 13 EXECUTION ACROSS THE PRODUCT LINES ViSafe (OHS) For personal use only • Launched OHS product into the UK and the US • New contracts with major OHS clients in UK & US (Toyota, Jaguar, Caterpillar, Weyehaueser) • Repeat & large scale OHS contracts (TFL, Crown and Monash/Allianz) • Developed and
Slide 14: Reducing Costs & Injury, Improving Productivity, Building Safety Culture
// 14 For personal use only REDUCING COSTS & INJURY IMPROVING PRODUCTIVITY BUILDING SAFETY CULTURE INSPIRING THE WORLD TO MOVE WELL™
Slide 15: Changing Occupational Health & Safety Forever
// 15 CHANGING OCCUPATIONAL HEALTH & SAFETY FOREVER For personal use only • Work injuries cost $250B p.a. (US) • Large untapped market with appetite for data • Unique IP leading to reduced injuries & costs • Interventions involving: • Job assessment • Equipment change • Pre-employment screening • Be
Slide 16: ViSafe in Action
// 16 ViSafe IN ACTION For personal use only Putting ‘Train Stop’ to gauge Remove ‘Train Stop’
Slide 17: dorsaVi ViSafe
dorsaVi ViSafe™ // 17 For personal use only Problem for major corporates: • Lack of visibility on injuries and costs • Poor ability to understand and change issues dorsaVi offering: • ViSafe projects (real data from the field) • Provides insights, risk matrix and solutions • Now offers an ongoing ba
Slide 18: Delivering Bottom Line Benefits
// 18 DELIVERING BOTTOM LINE BENEFITS Prior to dorsaVi Intervention • Case study from large organisation For personal use only 40 • Used dorsaVi sensors to identify risk & plan changes Number of injuries 35 30 • Third party provided pre-employment screening with ViMove 30 • Consumable revenue from 3
Slide 19: Scalable Revenue Model
// 19 SCALABLE REVENUE MODEL For personal use only Operational ViSafe • Assessors, Analytics, Reports, Solution, Implementation Scalability • Direct sales representatives in key markets • Sales partnerships with agents (win work and provide assessors) • Building relationships with Insurers and Insur
Slide 20: FDA Cleared, CE Mark, TGA Supported by Clinical Trial Data
// 20 For personal use only FDA CLEARED, CE MARK, TGA SUPPORTED BY CLINICAL TRIAL DATA INSPIRING THE WORLD TO MOVE WELL™
Slide 21: US Health Market Looking for Cost Saving
// 21 US HEALTH MARKET LOOKING FOR COST SAVING For personal use only Healthcare technology will reduce the burden on $560B health systems globally by: • Improving decision making & timely intervention • Allowing point-of-care diagnosis and treatment • Safe and clinically proven care • Personalised t
Slide 22: Clinical Evidence Shows Dramatic Change in Back Pain
// 22 CLINICAL EVIDENCE SHOWS DRAMATIC CHANGE IN BACK PAIN For personal use only $800,000 Long term disabled dorsaVi Impact Opioids dependence Spinal Cord $600,000 Stimulation, Opioids Repeat Spinal Surgery, Opioids $400,000 Surgery, Fusion, Opioids $200,000 Referral to MRI / Repeat Surgeon, Opioids
Slide 23: Significant Untapped Opportunity
// 23 SIGNIFICANT UNTAPPED OPPORTUNITY For personal use only 10 devices in FY15 80 devices in FY16 160 devices in 25 devices added in Q1 FY17 the market 24,000 physios (0.5% penetration) 85 devices in the market 48,000 physios 105 devices in the market 284,000 physical therapists
Slide 24: Clinical Platform to Manage Data, Reports and Communication
// 24 CLINICAL PLATFORM TO MANAGE DATA, REPORTS AND COMMUNICATION For personal use only Insurer PATIENT REPORTS AND DATA $ Doctor Employer Patient Specialist Physio Hospital Live Assessment Live Training Monitoring Biofeedback Exercises Reports
Slide 25: Clinical Sales and Revenue Model
// 25 CLINICAL SALES AND REVENUE MODEL For personal use only Targeting large and company-owned franchise networks • UK – YPP • USA – MeyerPT • Relationship with Select Medical (pilot with 20 of their 2,000 sites) Collaborative product developments • Product currently commercially released: ViPerform
Slide 26: Branding and Credibility
// 26 For personal use only BRANDING AND CREDIBILITY INSPIRING THE WORLD TO MOVE WELL™
Slide 27: Elite Sports Market: Working with the Innovators
// 27 ELITE SPORTS MARKET: WORKING WITH THE INNOVATORS For personal use only • Working with thought leaders • Optimising algorithms to meet market needs • Test market for future consumer product
Slide 28: Outlook
For personal use only Outlook // 28
Slide 29: Product Evolution: First Mover Advantage
// 29 PRODUCT EVOLUTION: FIRST MOVER ADVANTAGE For personal use only
Slide 30: Planned Product Releases on New Sensor Platform
// 30 PLANNED PRODUCT RELEASES ON NEW SENSOR PLATFORM For personal use only Launch of myViSafe™ New cloud-based New cloud-based • Mini sensors clinical application for: clinical application for: • Manual Handling App • Running • Low Back • Video training • Knee • Walking • Pre employment screening •
Slide 31: World Leaders Using dorsaVi Technology
// 31 WORLD LEADERS USING dorsaVi TECHNOLOGY For personal use only • • Unique insights coming from these commercial research projects Each project will lead to multiple new publications and potential new IP 65+ RESEARCH PROJECTS • 45,000 individual data sets and building daily • Medical device and p
Slide 32: Upcoming Newsflow
// 32 UPCOMING NEWSFLOW For personal use only • Recruitment of first patient into US low back registry • New OHS contracts with major corporates (US, UK & Australia) • Publication of Health Economic evaluation from large clinical trial • Launch of myViSafe into OHS market • Appointment of US distrib
Slide 33: dorsaVi contact details
// 33 dorsaVi™ For personal use only Andrew Ronchi PhD (Eng), B.App.Sci (Physio) Chief Executive Officer Level 1, 120 Jolimont Road, East Melbourne, Victoria 3002 Office: +61 9652 2192 | Mobile: +61 417 882 267 ar@dorsaVi.com | dorsaVi.com